广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 广州金域医学检验集团股份有限公司 会议资料 二〇二五年九月 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议议程 .... 3 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议须知 .... 5 议案一：关于取消公司监事会并修订《公司章程》及相关议事规则的议案 ... 7 议案二：关于修订《广州金域医学检验集团股份有限公司关联交易管理制度》的 议案三：关于修订《广州金域医学检验集团股份有限公司对外投资管理制度》的 议案四：关于修订《广州金域医学检验集团股份有限公司对外担保管理制度》的 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 广州金域医学检验集团股份有限公司 会议时间：2025 年 9 月 9 日 14:30 网络投票时间：2025 年 9 月 9 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平 台 的 投 票 时 间 为 2025 年 9 月 9 日 的 交 易 时 间 9 ...

广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会 会议资料 二〇二五年九月 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 目录 | 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议议程 3 | | --- | | 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议须知 5 | | 议案一：关于取消公司监事会并修订《公司章程》及相关议事规则的议案 ... 7 | | 议案二：关于修订《广州金域医学检验集团股份有限公司关联交易管理制度》的 | | 议案 9 | | 议案三：关于修订《广州金域医学检验集团股份有限公司对外投资管理制度》的 | | 议案 10 | | 议案四：关于修订《广州金域医学检验集团股份有限公司对外担保管理制度》的 | | 议案 11 | | 附件 1：广州金域医学检验集团股份有限公司章程 12 | | 附件 2：广州金域医学检验集团股份有限公司股东会议事规则 65 | | 附件 3：广州金域医学检验集团股份有限公司董事会议事规则 84 | | 附件 ...

截至8月27日收盘，基因测序概念下跌3.38%，位居概念板块跌幅榜前列，板块内，广生堂、睿昂基 因、谱尼测试等跌幅居前，股价上涨的有6只，涨幅居前的有迪安诊断、埃科光电、金域医学等，分别 上涨5.81%、3.67%、2.11%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | F5G概念 | 0.46 | 钛白粉概念 | -3.88 | | 中国AI 50 | 0.36 | 兵装重组概念 | -3.63 | | 共封装光学(CPO) | 0.18 | 天津自贸区 | -3.49 | | 稀土永磁 | 0.10 | 太赫兹 | -3.40 | | 智能音箱 | -0.27 | 基因测序 | -3.38 | | WiFi 6 | -0.46 | 细胞免疫治疗 | -3.29 | | MLOps概念 | -0.49 | 猴痘概念 | -3.25 | | 星闪概念 | -0.62 | 血氧仪 | -3.25 | | MCU芯片 | -0.66 | 幽门螺杆菌概念 | -3.24 | | 国家大基金持股 | -0.72 ...

8月27日早盘，AI智能体概股表现活跃，截至9时31分，能科科技涨停收获2连板，酷特智能涨逾8%，盈 康生命、万兴科技、豆神教育等跟涨。 上证报中国证券网讯 8月27日早盘，AI智能体概股表现活跃，截至9时31分，能科科技涨停收获2连板， 酷特智能涨逾8%，盈康生命、万兴科技、豆神教育等跟涨。 | 序号 | 代码 名称 | | | 涨幅% J | | | --- | --- | --- | --- | --- | --- | | 1 | ୧୦38829 | 能科科技 | 53.02 | 10.00 | 4.82 | | 2 | 300840 酷得智能 | | 25.90 | 8.78 | 2.09 | | 3 | 300143 盈康生命 | | 11.27 | 6.82 | 0.72 | | র্ব | 688500 慧辰股份 | | 81.30 | 6.14 | 4.70 | | 5 | 300624 万兴科技 | | 89.88 | 6.14 | 5.20 | | 6 | 300010 豆神教育 | | 10.10 | 5.65 | 0.54 | | 1 | 300496 中科创达 | | 72.35 | ...

金域医学 20250825 摘要 金域医学面临医疗行业挑战，包括医保控费、检验价格下行及行业规范 化，但长期来看，这些政策有助于合规企业发展，并增加外包服务需求， 为公司带来增长机会。公司坚持长期主义，通过变革措施确保基本面稳 健，并积极适应政策变化。 医疗检验行业面临物价下降和医保控费的双重压力，导致市场规模缩小 和检验项目价格下降。但第三方独立实验室有望获得更大市场份额，因 医院可能外包检测以应对成本压力，金域医学正积极适应这一趋势。 公司正从旧规则向新规则过渡，业绩承压。通过提供高价值服务、成本 控制和数字化转型应对挑战。自 2020 年起，公司在数字化、智能化建 设方面投入资源，以提高效率并降低成本，坚持核心价值导向。 金域医学在数据治理方面取得显著成就，成为全国首个建立可信数据空 间的医疗机构，并得到国家数据局认可。通过三年多的数据治理，实现 数据质量提升，并获得合作医院的高度认可。 公司高度重视产学研合作，与超过 210 家高校和医院以及腾讯、华为、 阿里等企业合作，增强科研实力，推动产业生态建设，实现稳健发展。 产学研结合是公司发展战略之一。 Q&A 金域医学在 2025 年上半年的业绩表现如何 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, anticipating a reversal in the market by 2025, with innovative drugs and the recovery of left-side sectors being the main investment opportunities [5][13]. Core Views - The report highlights that major domestic pharmaceutical companies have stabilized their revenues after previous disruptions from centralized procurement, with visible results from their innovation transformations [2][12]. - It emphasizes the importance of BD (business development) collaborations, citing significant deals involving major multinational pharmaceutical companies, which could lead to sustainable income for companies like Heng Rui Medicine [2][12]. - The report suggests focusing on innovative drugs, particularly dual/multi-target antibodies and drugs addressing unmet clinical needs, as key investment opportunities [3][5][13]. Summary by Sections Pharmaceutical Sector - The innovative drug market is experiencing adjustments, but the overall policy environment remains supportive for innovation [3]. - After ten rounds of centralized procurement, the risks for leading pharmaceutical companies are gradually being alleviated, revealing competitive innovative drug pipelines [3][22]. - The report recommends paying attention to leading pharmaceutical companies' transformation results and overseas opportunities [3][5]. Biopharmaceuticals - Jin Sai Pharmaceutical's dual-target ADC GenSci143 has received IND approval, showing potential as a leading treatment option for prostate cancer and other solid tumors [3][41][46]. Medical Devices - The registration and promotion of innovative products in the domestic medical device sector are accelerating, contributing to long-term high-quality development [4][47]. - Companies like Huitai Medical have reported significant revenue growth, with innovative products rapidly expanding their market presence [4][47][48]. Traditional Chinese Medicine - Some companies are facing performance pressure during the destocking cycle, but strong brands like Dong'e Ejiao continue to achieve resilient growth [4][54][56]. Investment Recommendations - The report suggests focusing on innovative drugs, particularly in the fields of dual/multi-target antibodies and drugs for chronic diseases, as well as opportunities in ADC and small nucleic acid sectors [5][13]. - The medical device sector is expected to see a significant performance turnaround in the second half of the year, driven by favorable policies and recovering tender trends [5][13]. Key Targets - Notable companies to watch include Innovent Biologics, Kintor Pharmaceutical, and Heng Rui Medicine, among others [6].

据证券之星公开数据整理，近期金域医学（603882）发布2025年中报。截至本报告期末，公司营业总收 入29.97亿元，同比下降22.78%，归母净利润-8480.68万元，同比下降194.6%。按单季度数据看，第二季 度营业总收入15.3亿元，同比下降24.97%，第二季度归母净利润-5702.16万元，同比下降152.66%。本报 告期金域医学公司应收账款体量较大，当期应收账款占最新年报营业总收入比达57.18%。 合同资产变动幅度为-37.8%,原因:随经营规模变化相应减少。 其他流动资产变动幅度为-35.2%,原因:预缴所得税减少。 开发支出变动幅度为51.85%,原因:数据资源开发投入增加。 其他非流动资产变动幅度为55.44%,原因:构建长期资产预付款增加。 应交税费变动幅度为-45.75%,原因:应交所得税减少。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率33.93%，同比减2.37%，净利率-3.23%， 同比减250.66%，销售费用、管理费用、财务费用总计7.04亿元，三费占营收比23.47%，同比增 18.36%，每股净资产14.73元，同比减11.95%，每股经营性现金流0 ...

Core Viewpoint - Guangzhou Kingmed Diagnostics Group Co., Ltd. reported a net loss of 85 million yuan in the first half of 2025, despite achieving an operating income of 2.997 billion yuan and a significant increase in operating cash flow by 920% year-on-year to 350 million yuan [1] Group 1: Financial Performance - The company experienced a net profit loss of 85 million yuan due to credit impairment losses of 272 million yuan [1] - Operating cash flow improved significantly, reaching 350 million yuan, marking a year-on-year growth of 920% [1] Group 2: Market Position and Collaborations - The revenue proportion from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [2] - Kingmed has established partnerships with over 210 hospitals, universities, and research institutions, including collaborations with top-tier hospitals for multi-center research and laboratory construction [2] Group 3: AI and Technological Advancements - The company launched the "AI IN ALL" initiative, developing 55 intelligent applications to enhance business processes [3] - AI-assisted diagnostics were utilized 2.2 million times in laboratories, improving efficiency, particularly with a 70% increase in report issuance efficiency for tumor molecular reporting systems [3] Group 4: Data and Compliance Initiatives - Kingmed accumulated over 3 billion medical testing data and successfully launched 21 data products on data exchanges in major cities [4] - The company was selected as the only medical institution in the first batch of national trusted data space innovation development pilots, facilitating compliant data circulation and exploring new data flow possibilities [4]

Core Viewpoint - The company reported a total revenue of 2.997 billion yuan for the first half of 2025, with a net profit attributable to shareholders of -85 million yuan, while operating cash flow improved significantly to 350 million yuan, a year-on-year increase of 920% [1] Group 1: Financial Performance - Total revenue for the first half of 2025 was 2.997 billion yuan, with a credit impairment loss of 272 million yuan, resulting in a net profit of -85 million yuan [1] - Operating cash flow reached 350 million yuan, reflecting a year-on-year growth of 920% [1] Group 2: Industry Context - The medical testing industry is undergoing a deep adjustment period driven by multiple factors including healthcare reform, technological revolution, ecological restructuring, and data application [1] Group 3: Competitive Advantages - The company has established a differentiated competitive advantage through product portfolio optimization, continuous innovation, and the development of regional testing center solutions [1] - The company has also built a cost competitive advantage through lean operations and intelligent empowerment [1] Group 4: Product Growth - The company launched several high-cost performance products in oncology, infectious diseases, and Alzheimer's early screening, achieving significant revenue growth: 85% for the "惠民3000" series, 49.99% for the Meta series, and 68.43% for the Alzheimer's screening series [1] - The revenue proportion from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [1] Group 5: Collaborative Efforts - The company has established partnerships with over 210 hospitals, universities, and research institutions, including collaborations with top-tier hospitals for multi-center research and joint laboratory construction [2] Group 6: AI Integration - The company launched the "AI IN ALL" initiative, developing 55 intelligent applications that enhance business process automation, with AI-assisted diagnostics being utilized 2.2 million times annually [3] - The "小域医" application has over 60,000 active doctors monthly and has processed over 3.6 million report interpretations [3] Group 7: Data Utilization - The company has accumulated over 3 billion medical testing data entries and successfully launched 21 data products on various data exchanges [4] - The company was selected as a pilot for the national trusted data space innovation development, being the only medical institution included [5]

证券代码：603882 证券简称：金域医学 公告编号：2025-037 广州金域医学检验集团股份有限公司 关于召开2025年第二次临时股东会的通知 一、召开会议的基本情况 (一)股东会类型和届次 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 9 日 14 点 30 分 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月9日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 9 日 至2025 年 9 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30 ...